Are benefits of the new Alzheimer's drug overblown?

The cost, time burden, and potential side effects of a new Alzheimer's drug may not be worth the minimal benefit, research suggests.

Related Keywords

United States ,Americans ,Mark Ebell ,College Of Public Health ,Drug Administration ,Michigan State University ,University Of Georgia ,Family Medicine ,Public Health ,Mini Mental State ,Michigan State ,